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Summary.-In tumour regrowth-delay experiments, the analysis of results in the
higher dose ranges may be complicated by a dose-dependent proportion of non-
recurrent (cured) tumours, whose inclusion in the analysis is not straightforward.
A study of the relation of growth delay to cure has been carried out using a model
of tumour response which assumes Poisson (single-cell) cure statistics and exponen-
tial regrowth kinetics of recurrent tumours, and which makes use of Monte Carlo
simulation techniques to represent the effects of inter-tumour heterogeneity. This
approach yields correction factors compensating for tumour cures in growth-delay
experiments. For homogeneous tumour systems (all tumours and treatments
identical) these corrections are small and not significantly different from corrections
obtained using the "long delay" procedure suggested previously (Denekamp, 1980;
Fowler et al., 1980). For heterogeneous systems, however, correction factors increase
with the heterogeneity of the system, and may become quite large.
It is concluded that the quantitative assessment of heterogeneity is required, and
a possible approach to this is suggested. Should evaluation of heterogeneity prove
feasible, it will allow more efficient use of tumour-response data, and may permit
realistic estimates of clonogenic cell survival in situ.
ONE OF the most popular end-points of
tumour response in situ to cytocidal treat-
ment is the mean regrowth delay of
recurrent tumours. Where, as in the lower
dose-ranges of the treatment, all tumours
are recurrent, calculation of mean or
average delay for a treatment group
presents no problem.
However, at least with the more effec-
tive treatment modalities, higher doses
produce an increasing proportion of non-
recurrent (cured) tumours which yield no
physically observable measure of growth
delay at all. The calculation of an average
growth delay for a treatment group
which includes both recurrent and non-
recurrent tumours is less straightforward,
and has led to some divergence of opinion
as to how such an analysis should pro-
ceed (see Kallman & Begg, 1980 for a
summary).
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One approach (Denekamp, 1980;
Fowler et al., 1980) is to include nominal
delays for non-recurrent tumours in the
form of "long delays" (i.e. as the esti-
mated time to tumour recurrence from a
single surviving clonogen i.e. cell) and
thus include cured tumours in the growth-
delay data to be averaged. As shown by
Fowler et al. (1980) this yields a pleasing
consistency between enhancement-ratio
estimates derived from growth delay and
from curability (e.g. TCD50) endpoints in
several experimental situations.
Despite the intuitive appeal of this
approach, its formal mathematical status
remains unexplored. Since the problem
of making allowance for cured tumours in
growth-delay experiments is a very com-
mon one, it may be worthwhile to attempt
to develop a formal mathematical treat-
ment.T. E. WHELDON AND G. F. BRUNTON
The objectives of growth-delay
experiments andtheproblemofnon-recurrent
tumours
In most experiments in which growth
delay is measured, the object (not always
explicit) is to use an end-point which
reflects the degree of cellular de-popula-
tion of the tumour by the treatment, in
effect a measure of the level of clonogenic
cell survival in treated tumours. The
relation of clonogenic cell survival to
observed growth delay is by no means
straightforward, and is considerably com-
plicated by factors such as the "tumour
bed effect" and the possible existence of
"second waves of delay" in some tumours
(see McNally, 1974; Brown & Howes,
1974, for a discussion) but it is unlikely
that growth delay would be a popular
end-point were it not considered to be (at
least roughly) representative of the level
of tumour-cell survival in situ. Indeed, if
growth delay proves not to provide a
valid index of the effectiveness of treat-
ment in killing clonogenic cells (rather
than, say, altering their growth character-
istics) then its use in most situations
(including the determination of "enhance-
ment ratios") will have been misplaced.
It is, therefore, advisable to check, where
possible, the agreement (or otherwise) of
growth delay and other assays, as carried
out, for example, by McNally et al. (1978)
for sensitizer enhancement ratios for
misonidazole in vivo and in vitro.
Here we shall adopt the conventional
view that the growth-delay end-point may
indeed be used as a measure of the
effectiveness of treatment in killing clono-
genic tumour cells-of reducing the
tumour-cell population to a certain sur-
vival level. In such cases, it is required
that the mean growth delay for a tumour
group should adequately reflect the mean
cell-survival level within the group as a
whole, not some atypical survival level
for some atypical sub-group of tumours.
Unfortunately, for treatments within the
range of curability, growth delay can be
directly assigned only to tumours which
are seen to recur; i.e. to the sub-group
least affected by the treatment. The sub-
group most affected by the treatment
("cured" tumours) do not recur and there-
fore provide no observed data for calcula-
tion of growth delay. Herein lies the
potential for bias by neglecting "cured"
tumours in growth-delay experiments,
and thus the need for some statistically
fair way oftaking account ofthem.
The homogeneous Poi8son mnodelfor tumour
cure and recurrence
Consider a population of identical
tumours, each containing an identical
number of clonogenic tumour cells, any
one of which is capable of repopulating
the tumour (note that this condition
excludes immunogenic tumours). A true
"cure" (no recurrence however long de-
layed) therefore requires elimination of
all clonogenic cells, so that each cured
tumour contains no surviving clonogenic
cells after treatment.
However, for most cytocidal agents
(radiation, most drugs) cell kill is a ran-
dom process, whereby, at any given dose
level, each clonogenic cell has a prob-
ability ofbeing eliminated or of surviving.
Hence, in a group of tumours given the
same treatment, a proportion of tumours
will be cured (no surviving clonogenic
cells) and a proportion will recur (at least
one surviving clonogenic cell).
Thus, in a group of K treated tumours,
the first tumour may have N1 surviving
cells, the second N2 and so on, the Kth
tumour having NK cells, some of these N
values (those for the cured tumours)
being zero.
Let N denote the arithmetic average for
the whole group.
This is a situation to which Poisson
statistics is readily applied, and it has
been shown by several authors (e.g.
Munro & Gilbert, 1961) that, if N is the
average clonogenic cell numberper tumour
for a tumour group, then Pe, the prob-
ability of cure for an individual tumour
(i.e. the probability that a particular
tumour contains zero clonogenic cells
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when the group average is N) is given by:
Pe =exp. (-N) (1)
The probabilities that a particular tumour
contains larger numbers of cells may be
found from higher terms in this Poisson
expansion.
This implies that the average number
of surviving clonogenic cells per tumour
may be computed from knowledge of the
probability of cure, Pe (in practice, the
proportion cured), viz.
N= -lnPc
TABLE.--Mean number of surviving cells
per tumour for all tumours (N) and for
recurrent tumours (NR) as a function of
proportion cured (PC) in homogeneous
system (tumours and dosages).
PC
0 05
0-10
020
0 30
0 37
0.50
0 75
0.95
099
(2)
N
3 00
2 30
1 61
1 20
1 00
0 69
0 29
0 05
0-01
NR
3*16
2 56
2*01
1 71
1 59
1 38
1*16
1o00
NR/N
1.05
1*11
1-25
1 43
1 59
2.00
4-00
20
100
The first two columns of the Table
show the relationship of N to Pc for a
range ofPc values from 0 05 (5% cured) to
0-99 (99% cured). It should be noted that
N is exactly 1 when Pc is 0 37 (i.e. at the
TCD37 dose level) and that N is fractional
for all higher values of Pc. Of course, a
fractional value of N does not imply that
any particular tumour has a fraction of
a clonogenic cell; fractional values arise
by averaging over all tumours, some of
which have (say) 1 or 2 cells, whilst other
(cured) tumours have no clonogenic cells
left. On this basis, there is no limit to how
small N can become; in a group of 100
tumours, for example, of which 99 were
cured (no cells) and 1 recurred from a
single cell, the value of N would be 0-01.
By contrast, those tumours which
actually do recur must have had at least
one surviving clonogenic cell. Ifwe denote
by NR the mean number of clonogenic
surviving cells per tumour averaged over
the sub-group of recurrent tumours only,
it is clear that NR could be never less than
unity. Indeed, there is a simple relation-
ship between N, NR and P,:
17 N I -PC (3)
This formula essentially modifies the
group average N by excluding the propor-
tion (Pa) of tumours for each of which the
surviving cell number is 0.
The values of N and NR corresponding
to a range of values of Pc are contrasted
NR / N
6
4-
2L
0_
0
Proportion cured ( Pc )
FIG. 1. Relation of the ratio of the mean
number of cells per recurrent tumour (NR)
to the meannumber ofcells per tumour (N),
as a function ofprobability ofcure (P,), for
a perfectly homogeneous tumour system.
The points shown are the individual data
points obtained by simulation.
in the Table, the last column of which
gives the ratio of NR to N, which reflects
the magnitude ofthe difference.
As may be seen from the Table, and
graphically, from Fig. 1, the magnitude
of the ratio NR/N increased rapidly
beyond a Pc of about 0.5, becoming very
large at high levels of tumour cure.
Indeed, the factor has no finite limit and
is theoretically infinite at total (100%)
curability.
It is this factor which causes the bias
when cured tumours are ignored in the
results of growth-delay experiments.
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Effect of inter-tumour heterogeneity on
distributions of surviving clonogenic cells
In the preceding analysis, it was explic-
itly assumed that the tumour system
wasperfectlyhomogeneous (i.e. alltumours
identical, all treatments identical). This
is, of course, an unattainable ideal to
which real systems approximate more or
less well. More generally, inter-tumour
heterogeneity will occur, and it is import-
ant to consider its effects. Inter-tumour
heterogeneity, in the form of variable
sensitivity to treatment, or, equivalently,
of treatment dose received, is especially
likely to occur in the case of treatment
modalities for which uniformity of dose
is difficult to achieve (e.g. hyperthermia,
cytotoxic chemotherapy) resulting in the
non-equivalence of individual tumours
within the same treatment group.
In the present study, the effect of inter-
tumour heterogeneity has been investi-
gated using a Monte Carlo simulation
model, described in the Appendix. Briefly,
each individual tumour was assigned a
sensitivity parameter (Do) randomly sel-
ected from a normal distribution of Do
values with specified mean and standard
deviation. The standard deviation of the
sensitivity distribution then provides a
measure of the level of heterogeneity.
The theoretical fraction of surviving cells
for each individual tumour subjected to a
given treatment dose was calculated using
a multi-target function for the randomly
assigned Do; the theoretical surviving cell
number (which could be an integer or
fractional) was then taken as the mean of
a Poisson distribution, and a random
number selected from this distribution to
represent the actual number of surviving
cells (an integer or zero) for each tumour.
Tumours assigned zero surviving cells
were deemed cured and those assigned at
least one surviving cell were deemed
recurrent.
By carrying out a large number of such
simulations for a range oftreatment doses,
and by varying the standard deviation of
the sensitivity (Do) distribution, it was
possible to study the effects of the sim-
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FIG. 2.-The effect of heterogeneity on the
ratio ofNR to N. Heterogeneity is generat-
ed by random selection of a Do-value for
each tumour from a normal distribution of
Do. The fractional standard deviation of
the distribution of Do (s.d./mean %) pro-
vides a measure of the heterogeneity. The
graph shows smooth curves drawn through
large numbers of data points (not shown)
obtained by simulation. The symbols are
for indentification only.
ulated heterogeneity (i.e. standard devia-
tion oftheDo distribution) on the numbers
of surviving cells per tumour (N) and per
current tumour (NR) as a function of the
proportion (Pc*) of cures obtained in each
treatment group.
The results, depicted in Fig. 2, show
that inter-tumour heterogeneity may have
a profound effect on the numbers of
surviving cells, averaged over all tumours,
or over recurrent tumours only. The dis-
crepancy factor N/SR is strongly influ-
enced by the heterogeneity and increases
with the fractional standard deviation of
the sensitivity distribution. It is not
difficult to see how this comes about. In
heterogeneous systems, the more sensitive
tumours are cured at treatment dose levels
which leave relatively large numbers of
surviving cells in the more resistant
tumours. Since the recurrent tumours are
likely to be the more resistant ones, a
large discrepancy may develop between
the average number of surviving cells per
tumour (N) and per recurrent tumour
(NR). The practical effect of this is that
711-I.Q ;i. .,:Z--,-...
'. '.. '' -
__Apo
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the presence of tumour
growth-delay experiments,
increasingly distorted as
increases.
Effects of the discrepancy
on growth delay
cures distorts
which become
heterogeneity
factor (N/NR)
In order to proceed from numbers of
surviving cells to growth delay, it is first
necessary to determine the growth law for
thetumour. Forexperimental tumours, the
available evidence indicates a composite
growth curve with an exponential (latent)
phase giving way to a decelerating Gom-
pertzian phase (see Steel, 1977 for discus-
sion). The Gompertzian phase may, in
itself, lead to some complications in the
interpretation ofgrowthdelayexperiments
(Begg, 1980).
However, for most experimental tum-
ours, growth is exponential for most of
the growth range (e.g. from 1 cell to 106 or
107 cells). The present analysis is restricted
to the case ofpurely exponentialregrowth.
It is unlikely that this restriction seriously
affects the conclusions reached.
With the assumption of exponential
regrowth it is possible to determine the
tumour regrowth delay corresponding to
particular numbersofsurviving cells. Thus,
for exponential growth at specific rate A,
a tumour-cell population which has been
reduced to N surviving clonogenic cells by
the treatment will regrow to a population
size ofNo cells in TR where:
No=N exp (ATR) (4)
Let us now consider individual tumours
to be coded 1, 2, 3, . i ... m where there
are m recurrent tumours in the group.
Then TR(O), the regrowth delay for the
ith tumour is given by:
TR)= ln (No/Ni) (5)
where Ni is the number of surviving
clonogenic cells for the ith tumour. The
mean regrowth delay, TR for the recurrent
tumours is given by the arithmetic
average of the regrowth delay times
TR(t), TR(2) . . .TR(') . . .TR( ) for the m
individual recurrent tumours. (Note that
because of the logarithmic relationship
between growth delay and cell number,
the arithmetic average growth delay
corresponds to a geometric average of
cell number.)
Equation (5), used with the surviving
cell numbers previously generated by the
Monte Carlo procedure, allows calculation
ofthe mean growth delay for the recurrent
tumours at each dose. Since, in reality,
only tumours which are recurrent yield
measurable growth delay, this growth
delay (fR) is the growth delay which
would be observed experimentally.
Suppose, however, that a tumour was
capable of regrowing from less than 1 cell
(e.g. 041 cell or 0 01 cell). Such a tumour
would, of course, have a longer growth
delay than the longest physically possible
time (for growth from a single cell) and
this could be calculated using a similar
equation to equation (7). Fractional mean
levels of cell survival do indeed result
from calculation of the effects of large
treatment doses, using any continuous
survival model. (E.g., an initial popula-
tion of 108 cells would be reduced to 0.1
cells by a treatment giving a 10-9 surviv-
ing fraction.)
F-FWctcr
195O
1.40
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FIG. 3.-The relation of the "cure-correction
factor" (F) (see text) to proportion cured
(Pc*) for various levels of heterogeneity.
Heterogeneity is indicated by the % s.d.
of the Do distribution. The graph shows
smooth curves drawn through large num-
bers of data points (not shown) obtained
by simulation. The symbols are for
identification only.
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Though physical regrowth from less
than one cell is, of course, biologically
impossible, the theoretical regrowth delay
time is easily calculated, so that the
"regrowth time" of cured tumours can be
included in the analysis. When the re-
growth delay of all tumours (including
those deemed cured) are calculated in
this way, the individual growth delay
may then be averaged as before to yield
;, the mean growth delay for all tumours
in the group.
In this way it is possible to calculate a
theoretical mean growth delay for all
tumours and to compare it with the
corresponding growth delay for the recur-
rent tumours only. To facilitate compari-
son, it is useful to define a "cure correction
factor" (F) given by:
F= T/TR (6)
or
F=FInR (7)
i.e. the correction factor F is the quantity
by which the observed mean regrowth
delay (fR) must be multiplied, in order to
obtain the theoretical mean regrowth
delay (z) which takes account of cured
tumour.
Using the mathematical model and
Monte Carlo simulation procedure des-
cribedintheAppendix, thecure-correction
F factor has been calculated as a function
of the proportion of tumours cured (Pc*)
in each dose group, and as a function of
the heterogeneity of the system, i.e. as a
function of the standard deviation of the
sensitivity (Do) distribution.
The results are shown in Fig. 3. As
may be seen, the F factor rises as a func-
tion of the cured proportion, and is also
greater for greater heterogeneity. For per-
fectly homogeneous systems (zero varia-
tion of Do), the factor rises slowly from
1-00 (at a zero proportion of tumour
cures) to a value of 1 04 at a cured propor-
tion of 0.50. This is a very modest cor-
rection, and implies that neglect of cured
tumours produces no serious error in
perfectly homogeneous tumour systems.
However, the magnitude of the correc-
tion factor increases with the hetero-
geneity. For a heterogeneity correspond-
ing to 25% standard deviation of the
sensitivity distribution, the F factor has
risen to 1-17 for a cured proportion of 0 50
and to 1-32 by a cured proportion of 0-80.
This is a rather more serious correction
andindicates that neglectofcuredtumours
in such a tumour system could lead to
significant under-estimation of the effect
oftreatment.
It is instructive to compare these
numerical properties of the F factor with
the "long delay" correction procedure
suggested previously (Denekamp, 1980;
Fowler et al., 1980) to allow for cured
tumours in growth-delay experiments. In
this case, an "F factor" for the "long
delay" procedure (FLD) may be calcu-
lated by taking the ratio of the mean
growth delay obtained by assigning a
"long delay" (here taken to be the time to
regrow from a single cell) to curedtumours,
to the mean delay for recurrent tumours
only.
For the heterogeneity levels previously
considered, the "long delay" correction
factor was compared with the factor
derived here. For homogeneous systems,
and for only slightly heterogeneous sys-
tems, these factors were both small in
magnitude and did not differ significantly.
As the heterogeneity increased however,
the F factor derived here increased rapidly
1501-
1M4
1-30
L1-2
1.1t
-
0 o
@0 @00800 00O oB0 00*
1-LX'* .
0 0D20 0'I. 0-60 08
Proportion curd(Pc*)
FIG. 4. A comparison of the cure-correction
factor (F, 0) with the corresponding
factor (FLD, 0) obtained using the "long
delay" correction procedure, for a Do
distribution with a s.d. of 25%. The points
shown are the individual data points ob-
tained by simulation.
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and more consistently than the "long
delay" factor. This effect is illustrated in
Fig. 4, which compares the two correction
factors for heterogeneity corresponding
to 25% standard deviation in the sensi-
tivity (Do) distribution.
Evidently, the "long delay" procedure
could seriously underestimate the import-
ance of cured tumours in growth-delay
experiments involving the more hetero-
geneous tumour systems.
A possible approach to the quantitative
assessment ofheterogeneity
There seems little prospect of precisely
correcting for cured tumours in growth-
delayexperiments unless theheterogeneity
present can be quantified. This seems a
daunting prospect, but an approach to
the problem maybe possible.
In a perfectly homogeneous system, no
cures should be observed until the mean
number of surviving cells per tumour
becomes very low. Thereafter, a small
increase in treatment dose should lead to
a rapid rise in the proportion of cures.
In heterogeneous systems, however, the
more sensitive tumours will be cured
whilst the more resistant tumours regrow
from appreciable numbers of surviving
58
- *~
58
54-
52
Proportion curd (PL)
FIG. 5.-The effect of heterogeneity on the
relation of observed mean regrowth delay
(7rR) to proportion cured. Heterogeneity is
indicated by the % s.d. of the Do distribu-
tion. The graph shows smooth curves drawn
through large numbers of data points (not
shown) obtained by simulation. The sym-
bols are for identification only.
cells. Considerable increase in treatment
dose may be necessary before the more
resistant tumours are cured.
These considerations suggest that com-
parison of the observed regrowth delay
(for recurrent tumours) to the proportion
cured may indicate the heterogeneity
present in the tumour system. This is
illustrated in Fig. 5, which shows the
relation of observed growth delay to
proportion cured for varying levels of
heterogeneity. As expected, the observed
growth delay rises steeply to its plateau
value (the time to regrow from a single
cell) for homogeneous systems, but the
approach to the plateau level becomes
progressively less steep as the hetero-
geneity increases. It is possible, therefore,
that the shape of the curve relating obser-
ved growth delay to proportion cured
could be used to indicate the level of
heteterogeneity.
At the very least, a steep rise to the
plateau level of growth delay provides
confidence that the system under study is
relatively homogeneous (and that neglect
of cured tumours in growth-delay experi-
ments is relatively unimportant) whilst a
shallow rise provides a warning ofpossible
heterogeneity (and a potentially serious
effect of neglecting tumour cures). Since,
in general, homogeneous experimental
systems are preferable to heterogeneous
ones, this may provide a further criterion
for judging the suitability of the current
experimental system.
However, further work is necessary to
determine the practical feasibility of this
approach, and the extent to which compli-
cating factors may intrude. Amongst the
complicating factors which require to be
considered are the growth-kinetic changes
which may accompany treatment
(McNally, 1974; Brown & Howes, 1974;
Stephens & Peacock, 1977) and which are
already known to complicate the inter-
pretation of growth-delay experiments.
The effects of growth-rate variations
amongst regrowing tumours, and the
importance of sample size also require
further consideration.
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However, it seems possible that the
relation of growth delay to cure could
provide a rough estimate ofheterogeneity,
and such an approach may be worth
furtherinvestigation.
CONCLUSIONS
(1) In homogeneous tumour systems,
the observed regrowth delay rises steeply,
with proportion cured, to a plateau level.
In such systems, only a small correction
need be applied to the observed growth
delay to allow for cured tumours; this
correction is equally well made using the
"long delay" procedure or from informa-
tion presented in this paper.
(2) In non-homogeneous systems, the
relation of observed delay to proportion
cured rises more slowly. In such systems,
neglect of cured tumours in growth-delay
experiments may lead to a serious under-
estimation of the effectiveness of treat-
ment. The "long delay" procedure will,
ingeneral,provide correction factors which
are too small, again leading to under-
estimation of the effectiveness of treat-
ment. Accurate correction factors cannot
be derived without knowledge of the
heterogeneity ofthe system.
(3) It is possible that the relationship
of observed growth delay to proportion
cured might provide estimates of the
level of heterogeneity. Then, accurate
correction factors could be derived. It is
also possible that such information could
be used to allow the reliable estimation
ofclonogenic cell survival in situ.
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APPENDIX
Monte Carlo methods comprise that branch
of experimental mathematics which may be
used to simulate random physical processes
using sequences of suitably distributed ran-
dom numbers, and takes place using a com-
puter rather than a laboratory.
The present investigation uses random
numbers, first to introduce known degrees
of heterogeneity in radiosensitivity into
otherwise identical populations of tumours,
and then to simulate the response of the
individual members of these "experimental"
populations to the random physical process of
radiation cell kill, modelled by Poisson
statistics.
Random number generator
The random numbers used depend upon
a common source of uniformly distributed.
random numbers, generated using a multi-
plicative congruential generator (modulus 247
and generator 515), investigated by Coveyou
& MacPherson (1967); and upon a number
of machine-independent computer sub-
routines described and tested by McGrath &
Irving (1975), here implemented on a Data
General Nova 1200 Computer in Fortran.
Tumour system
The tumour system studied in these
simulations is characterized by the followingGROWTH DELAY AND CURE IN TUMOURS 9
"typical" parameter values:
Radiosensitivity (Do) =3-0 Gy.
Extrapolation number (n)=2.
Fraction of cure dominating clonogens
(f) =005.
Initial tumour-cell population (before
irradiation) against which the re-
growth delay is assessed (No) = 109 cells.
Exponential tumour-doubling time (TD)=
2 days.
Simulations
From this set of parameters 9 distinct
"experimental" populationswereconstructed,
each comprising 50 tumours, whose individ-
ual radiosensitivities (Doi) are randomly
selected from a normal distribution of Do
values with a mean value of 3 0 Gy and, for
each population, a certain heterogeneity, H,
expressed as s.d. as a percentage ofthis mean.
Computationally, the random selection of
elements from a normal distribution with a
known mean (Do) and standard deviation
(HDO) was made with an efficient algorithm
written by Marsaglia & Bray (1964). The
responses of each of these 9 populations to a
range of single radiation doses was simulated
in a process which, if carried out in the
laboratory, would require at least 204
separate irradiations and the use of at least
10,200 tumour bearing animals.
For each individual tumour characterized
by its randomly attributed radiosensitivity,
Doi, the average number ofcells, Ni, expected
to survive a single radiation dose, D (were
there many such identical tumours); may be
calculated theoretically from the high-dose
approximation to the multitarget equation:
Ni = nNo exp. (-D/Doi) (8)
Allowance for the random nature ofradiation
cell killing and the fact that each tumour is
considered individually, is made by using this
theoretical average surviving cell number, Ni,
to define a Poisson distribution for each
tumour from which the actual number of
surviving cells, Ni, in that tumour, is ran-
domly selected.
Computationally, the random selection of
elements from a Poisson distribution was
effected using a subroutine described by
McGrath & Irving (1975) except in those
cases where Ni> 10 cells, where an approxi-
mating normal distribution was used in the
interests of efficiency.
For each population and dose level, those
tumours assigned zero cells by this process,
were considered cured and the corresponding
proportion termed "the observed cure prob-
ability", Pd*. The radiation dose range used
for each population was adjusted so that this
probability always encompassed the range
041-0 9. Dose increments of 1D0 Gy were
adhered to throughout.
For each population and dose level, those
tumours assigned one or more surviving cells
were assumed to recur, constituting a popula-
tion subgroup from which "observations" of
regrowth delay are made. The geometric
average cell number NR, in this subgroup
may be obtained from the relation:
l M1
lnNR= lnNi; Ni$0 (9)
where M is the number of recurrent tumours
in a given population. The dependence ofthe
discrepancy factor (NRIN) upon the degree
of population heterogeneity may now be
investigated (see Fig. 2).
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